4//SEC Filing
Clague Laura 4
Accession 0001209191-22-006362
CIK 0001438533other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 4:17 PM ET
Size
14.8 KB
Accession
0001209191-22-006362
Insider Transaction Report
Form 4
Clague Laura
Chief Financial Officer
Transactions
- Award
Employee stock option (right to buy)
2022-01-31+39,360→ 39,360 totalExercise: $27.50Exp: 2032-01-30→ Common Stock (39,360 underlying) - Award
Common Stock
2022-01-31+9,840→ 39,093 total - Sale
Common Stock
2022-01-31$27.40/sh−1,238$33,921→ 37,855 total - Award
Performance-based restricted stock units
2022-01-31+9,840→ 9,840 total→ Common Stock (9,840 underlying) - Award
Performance-based restricted stock units
2022-01-31+8,000→ 8,000 total→ Common Stock (8,000 underlying)
Footnotes (6)
- [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.
- [F2]The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F3]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F4]Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F5]This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.
- [F6]This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001388773
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 4:17 PM ET
- Size
- 14.8 KB